Herborium Reports 23% Increase in Sales for Second Quarter of
2017
FORT LEE, NJ - June 08, 2017 - InvestorsHub NewsWire - Herborium
Group, Inc. (OTC Pink: HBRM), www.Herborium.com, a Botanical
Therapeutics Company and the provider of unique all botanical
medicinal products (Botanical Therapeutics) that target
dermatological issues such as acne, and other health and wellness
concerns, announced today that initial review of the Second Quarter
of 2017 shows 23% increase in Companys sales is in comparison to
the same period of 2016. .
The 23% increase in Herboriums revenue marks the15th consecutive
quarter of sales growth of the Companys proprietary, all herbal
ingredients based acne treatment AcnEase and is attributed to
successful execution of the specific aspects of Herborium Marketing
Strategy
- Opening of Hispanic Market in March 2017.$1.4 trillion Hispanic
market is an ideal match for Herborium products and account for
over 15% of the US e-commerce market. Hispanic purchasing power has
increased at a compound annual growth rate of 7.5%, which is more
than twice as fast as the 2.8% growth rate in the total U.S.
- Increasing the wholesale distribution.
Increasing Amazon sales
Very successful Social Media Strategy including:
- AcnEase US Facebook exceeds now 85,000 likes and AcnEase France
Facebook exceeds 75,000 likes. AcnEase Spanish Facebeook grew 5000%
in first 6 weeks after it has been launched
AcnEase Blog has be ranked No 1 acne skincare blog on Internet the
3rd consecutive year ( 2015, 2016, 2017.)
Outlook for the rest of 2017:
Herborium remains very optimistic about further growing its
business, sales and product awareness in the US and abroad for the
remaining half of 2017. ,
The Company continues its efforts to increase market penetration
in both retail and wholesale sectors.
The global nutraceutical market was valued at about $250 billion
in 2016 and is expected to reach around $385 billion by the year
2021. The United States nutraceutical market has dominated this
growth, accounting for approximately 36% of this growth. Herborium
is both excellently prepared and committed to take advantage of
this opportunity.
About Herborium Group, Inc.
Herborium Group, Inc. is a Botanical Therapeutics company that
develops, licenses and markets proprietary, botanical based
medicinal products to consumers and healthcare professionals. The
Companys business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. Herborium has
secured a pipeline of botanical ingredients based products in the
areas of dermatological needs, wellness and energy, prostate
health, womens health and selected sexual disorders resulting from
cardiovascular disease, use of anti-depressants, diabetes, surgical
procedures, and other issues. Herborium Group sells its products in
the United States, the United Kingdom, and continental Europe
through a network of distributors, specialty retailers, and
e-commerce. For more information, please visit www.herborium.com, www.acnease.com, www.acnease.fr.www.acneasesp.com, www.acnease.co.uk.
Safe Harbor Statement: This release contains forward-looking
statements with respect to the results of operations and business
of Herborium Group, Inc., which involves risks and uncertainties.
The Company's actual future results could materially differ from
those discussed. The Company intends that such statements
about the Company's future expectations, including future revenues
and earnings, and all other forward looking statements be subject
to the "Safe Harbors" provision of the Private Securities
Litigation Reform Act of 1995.
Contact Information:
Herborium Group, Inc.
Email: InvestorsRelations@Herborium.com or DrAgnes@Herborium.com